DiogenX is a preclinical stage biotechnology company based in Marseille, France, with additional research facilities in Nice. Founded in 2019, DiogenX specializes in developing pancreatic beta-cell modulators aimed at treating Type 1 and Type 2 diabetes. The company's primary focus is on creating a candidate molecule that regenerates pancreatic insulin-producing cells in diabetic patients, which has the potential to improve both quality of life and survival rates. This innovative approach to therapy was initially discovered in the laboratory of Dr. Patrick Collombat at Inserm, CNRS, and Nice University, positioning DiogenX as a pioneer in beta-cell regeneration for diabetes treatment.
Kriya Therapeutics, Inc. is a gene therapy company based in Palo Alto, California, with an additional office in Durham, North Carolina. Founded in 2019, the company specializes in designing and developing innovative treatments for chronic diseases that are both prevalent and severe. Kriya Therapeutics focuses on conditions with well-understood underlying biology, aiming to create one-time gene therapies that provide durable expression of therapeutic proteins in targeted human tissues. The company's team comprises experts and former leaders from prominent gene therapy firms and academic institutions. Utilizing algorithmic tools, scalable infrastructure, and proprietary technology, Kriya Therapeutics seeks to enhance the efficacy and longevity of its therapies, striving to redefine treatment approaches for serious health conditions.
Jaguar Gene Therapy is a clinical-stage biotechnology company focused on advancing gene therapy solutions for patients with severe genetic diseases. The company aims to address significant unmet medical needs by developing therapies that target nonworking or absent genes, introducing healthy copies of these genes to restore their function. By accelerating the process of bringing innovative gene therapies from research to clinical application, Jaguar Gene Therapy seeks to improve patient outcomes and enhance the overall standard of care for those affected by genetic disorders.
Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors designed to analyze body fluids for health monitoring. Founded in 2012 and originally known as Electrozyme LLC, Biolinq aims to enhance the experience of individuals with diabetes by providing a more affordable and pain-free alternative to conventional continuous glucose monitoring (CGM) systems. The company's platform features minimally invasive electrochemical biosensors capable of measuring multiple analytes, including glucose, ketones, and lactate. This innovative technology not only facilitates easier blood glucose monitoring but also delivers actionable insights into metabolic health, significantly improving the quality of life for patients managing diabetes.
GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) to treat a range of conditions, including autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and based in Boston, Massachusetts, with additional locations in Seattle and Israel, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs. This innovative approach aims to restore immune tolerance and address the limitations found in current regulatory T-cell therapies. The company was co-founded by experts in Treg biology and synthetic immunology, emphasizing its commitment to addressing the underlying causes of diseases linked to immune system dysfunction.
Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.
Kriya Therapeutics, Inc. is a gene therapy company based in Palo Alto, California, with an additional office in Durham, North Carolina. Founded in 2019, the company specializes in designing and developing innovative treatments for chronic diseases that are both prevalent and severe. Kriya Therapeutics focuses on conditions with well-understood underlying biology, aiming to create one-time gene therapies that provide durable expression of therapeutic proteins in targeted human tissues. The company's team comprises experts and former leaders from prominent gene therapy firms and academic institutions. Utilizing algorithmic tools, scalable infrastructure, and proprietary technology, Kriya Therapeutics seeks to enhance the efficacy and longevity of its therapies, striving to redefine treatment approaches for serious health conditions.
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with progressive multiple sclerosis (MS) and other severe autoimmune and inflammatory diseases.
Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying causes of thrombosis and type one diabetes. By leveraging a deep understanding of the molecular mechanisms associated with these conditions, the company seeks to create innovative treatment options that can lead to improved health outcomes for patients. Their focus includes therapies specifically targeting heparin-induced thrombocytopenia and thrombosis, with the goal of providing patients with effective solutions for complete recovery from diabetes and associated complications.
Code Biotherapeutics
Seed Round in 2021
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The Company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.
Seraxis is a private biotechnology company founded in March 2013, with operations in Singapore and the United States, and a GMP lab located in Germantown, Maryland. The company specializes in developing innovative cell replacement therapies aimed at treating insulin-dependent diabetes. Their primary focus is on creating a solution that allows for the production of insulin to manage glucose levels, providing patients with a long-term cure that does not necessitate immuno-suppression. Seraxis is dedicated to advancing its novel cell and encapsulation technologies to bring this treatment to clinical use as efficiently as possible.
Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets stabilized hypochlorous acid (HOCl) products for a range of healthcare applications, including wound care, dermatology, animal health, and eye care. The company offers a diverse portfolio of products designed to address various medical needs, such as Epicyn, an antimicrobial facial cleanser; Levicyn, for managing dermatoses; and Celacyn, which promotes healing of surgical scars and trauma wounds. Other notable products include SebuDerm for seborrheic dermatitis, Ceramax for dry skin, and Acuicyn for eye irritation. Sonoma also provides solutions for animal health, like MicrocynAH and MicrocynVS, targeting skin conditions in pets. With over 100 products commercialized globally across 33 countries, the company aims to enhance patient care while addressing unmet medical needs and reducing healthcare costs. Founded in 1999 and based in Woodstock, Georgia, Sonoma Pharmaceuticals was previously known as Oculus Innovative Sciences, Inc. before rebranding in 2016.
Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.
Enthera S.r.l. is an Italian biotechnology company established in 2016, based in Milan, and operates as a subsidiary of BiovelocITA S.r.l. The company focuses on developing innovative biologics aimed at treating diabetes and its related gastrointestinal complications, particularly enteropathy, as well as other intestinal disorders that share similar biological pathways. Enthera's research is centered on monoclonal antibody discovery and biotherapeutics that target mechanisms involved in cell apoptosis in the gut, pancreas, and other organs. By addressing these pathways, Enthera aims to provide effective treatments for underserved autoimmune conditions, thereby contributing to advancements in the management of type 1 diabetes and inflammatory bowel disease. The company's name reflects its mission, combining the terms "entero," relating to the intestine, and "therapy."
DiogenX is a preclinical stage biotechnology company based in Marseille, France, with additional research facilities in Nice. Founded in 2019, DiogenX specializes in developing pancreatic beta-cell modulators aimed at treating Type 1 and Type 2 diabetes. The company's primary focus is on creating a candidate molecule that regenerates pancreatic insulin-producing cells in diabetic patients, which has the potential to improve both quality of life and survival rates. This innovative approach to therapy was initially discovered in the laboratory of Dr. Patrick Collombat at Inserm, CNRS, and Nice University, positioning DiogenX as a pioneer in beta-cell regeneration for diabetes treatment.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
Kriya Therapeutics, Inc. is a gene therapy company based in Palo Alto, California, with an additional office in Durham, North Carolina. Founded in 2019, the company specializes in designing and developing innovative treatments for chronic diseases that are both prevalent and severe. Kriya Therapeutics focuses on conditions with well-understood underlying biology, aiming to create one-time gene therapies that provide durable expression of therapeutic proteins in targeted human tissues. The company's team comprises experts and former leaders from prominent gene therapy firms and academic institutions. Utilizing algorithmic tools, scalable infrastructure, and proprietary technology, Kriya Therapeutics seeks to enhance the efficacy and longevity of its therapies, striving to redefine treatment approaches for serious health conditions.
i2O Therapeutics, Inc. is a biotechnology company based in Saratoga, California, founded in 2019. The company specializes in developing oral formulations for therapies that are traditionally administered via injections. Utilizing its innovative ionic liquid technology, i2O Therapeutics aims to enhance the delivery of biologics by protecting the drug cargo and improving its absorption through the epithelial lining when taken orally. This approach focuses on creating next-generation oral therapies, particularly for peptides and proteins, which are typically challenging to deliver in pill form. The company's work addresses the need for safer and more convenient alternatives to injection-based treatments, targeting metabolic and inflammatory diseases.
Pandion Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for autoimmune diseases. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials to address various autoimmune and inflammatory conditions. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to facilitate tissue-selective immunomodulation in the gastrointestinal tract. PT001 combines a PD-1 agonist with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM), while PT002 merges an IL-2 mutein effector with a MAdCAM-binding module. The company has also established a collaboration with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. Headquartered in Watertown, Massachusetts, Pandion Therapeutics aims to create effective and safe treatments to improve patient outcomes in the field of autoimmune disorders.
Repertoire Immune Medicines is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on leveraging the capabilities of T cells to develop innovative therapies for cancer, autoimmune diseases, and infectious diseases. Founded in 2016, the company is engaged in clinical trials that utilize autologous T cells primed against specific cancer antigens, enhancing their effectiveness with IL-15. By creating a repertoire of T cell receptor (TCR)-antigen codes, Repertoire aims to characterize TCR-antigen pairs and design targeted immune medicines. This approach seeks to unlock the human immune system’s potential, providing new avenues for prevention and treatment of serious diseases.
Immunocore Limited is a biotechnology company specializing in the discovery and development of innovative T cell receptor-based therapeutics aimed at treating cancer, viral diseases, and autoimmune disorders. Founded in 1999 and headquartered in Abingdon, United Kingdom, with an additional office in Conshohocken, the company has developed a proprietary technology platform that enables the engineering of T cell receptors (TCRs) linked to antibody fragments. This expertise has led to the advancement of IMCgp100, a bi-specific immunotherapeutic currently undergoing clinical trials for metastatic melanoma. Immunocore's focus on addressing diseases with significant unmet medical needs underscores its commitment to advancing novel treatment options.
Immunocore Limited is a biotechnology company specializing in the discovery and development of innovative T cell receptor-based therapeutics aimed at treating cancer, viral diseases, and autoimmune disorders. Founded in 1999 and headquartered in Abingdon, United Kingdom, with an additional office in Conshohocken, the company has developed a proprietary technology platform that enables the engineering of T cell receptors (TCRs) linked to antibody fragments. This expertise has led to the advancement of IMCgp100, a bi-specific immunotherapeutic currently undergoing clinical trials for metastatic melanoma. Immunocore's focus on addressing diseases with significant unmet medical needs underscores its commitment to advancing novel treatment options.
IMTherapeutics is a biotechnology company focused on creating personalized immunotherapeutic drugs for autoimmune diseases, utilizing genetic insights linked to human leukocyte antigen (HLA) genes. Founded in 2015 and based in Aurora, Colorado, the company’s lead candidate is an oral medication designed to inhibit the autoimmune process in type 1 diabetes (T1D) by targeting specific immune cells. This approach aims to preserve the function of pancreatic beta cells and support normal insulin production in patients at risk or in the early stages of T1D. Additionally, IMTherapeutics is leveraging its HLA platform to expand its drug pipeline to include treatments for Celiac disease and potentially other autoimmune disorders. The company employs advanced screening techniques and rational drug design to develop targeted therapeutic candidates, enhancing early detection and management of autoimmune conditions.
Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying causes of thrombosis and type one diabetes. By leveraging a deep understanding of the molecular mechanisms associated with these conditions, the company seeks to create innovative treatment options that can lead to improved health outcomes for patients. Their focus includes therapies specifically targeting heparin-induced thrombocytopenia and thrombosis, with the goal of providing patients with effective solutions for complete recovery from diabetes and associated complications.
Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors designed to analyze body fluids for health monitoring. Founded in 2012 and originally known as Electrozyme LLC, Biolinq aims to enhance the experience of individuals with diabetes by providing a more affordable and pain-free alternative to conventional continuous glucose monitoring (CGM) systems. The company's platform features minimally invasive electrochemical biosensors capable of measuring multiple analytes, including glucose, ketones, and lactate. This innovative technology not only facilitates easier blood glucose monitoring but also delivers actionable insights into metabolic health, significantly improving the quality of life for patients managing diabetes.
ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT has developed a functional T-cell test that aids in diagnosing and monitoring the maintenance of immune tolerance in patients undergoing peptide-based therapy. By leveraging advancements in immunology, ImmusanT seeks to enhance the management of celiac disease and potentially other autoimmune conditions.
Capillary Biomedical is a medical device startup developing technologies for diabetes management. They aim to dramatically simplify glucose monitoring and insulin delivery, reducing the burden on both patients and the overall healthcare system. The company is based in Irvine, CA and is a spin-out of the Artificial Pancreas Center at the Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, PA.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.
Bigfoot Biomedical, Inc., a health solution company, develops automated insulin delivery systems for people with Type 1 Diabetes (T1D). It develops a T1D Management System with cloud connectivity and human-centered-automation; and insulin pumps. Bigfoot Biomedical, Inc. was formerly known as SmartLoop Labs, Inc. and changed its name to in Bigfoot Biomedical, Inc. February 2015. The company was incorporated in 2014 and is based in Milpitas, California.
Bigfoot Biomedical, Inc., a health solution company, develops automated insulin delivery systems for people with Type 1 Diabetes (T1D). It develops a T1D Management System with cloud connectivity and human-centered-automation; and insulin pumps. Bigfoot Biomedical, Inc. was formerly known as SmartLoop Labs, Inc. and changed its name to in Bigfoot Biomedical, Inc. February 2015. The company was incorporated in 2014 and is based in Milpitas, California.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.
Diasome Pharmaceuticals, Inc. is a clinical stage company focused on developing innovative diabetes therapeutics. The company specializes in insulin-based therapies, notably its hepatocyte directed vesicle (HDV), which acts as a nanoscale carrier delivering insulin directly to the liver. This technology allows for the delivery of 100 insulin molecules per disc and is compatible with various insulin delivery methods, including insulin pumps. In addition to HDV, Diasome offers products such as Oral HVD-I, a targeted oral insulin, and both injectable short-acting (HDV-I) and long-acting (HDV-B) insulins. The company aims to improve treatment options for patients with Type 1 and Type 2 diabetes. Founded in 2004, Diasome Pharmaceuticals is based in Conshohocken, Pennsylvania.
TetraGenetics, Inc. is a biotechnology company focused on developing therapeutic proteins and vaccines for the biopharmaceutical industry. Established in 2004 and headquartered in Arlington, Massachusetts, the company utilizes its proprietary TetraExpress system to produce recombinant human ion channel proteins and other complex proteins. TetraGenetics offers products such as IchVax, a recombinant subunit vaccine aimed at preventing white-spot disease in freshwater fish. The company's platform leverages the protist Tetrahymena thermophila to efficiently generate properly folded, functional transmembrane proteins, which are often difficult to express using traditional methods. This technology supports the development of vaccine antigens, monoclonal antibodies, and therapeutic proteins for both human and animal health. Additionally, TetraGenetics has formed a strategic research and development collaboration with Imbrium Therapeutics L.P. to further enhance its offerings in the field of autoimmune diseases and pain management.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
GluSense is developing a miniature implantable continuous glucose sensor. The sensor will be implanted under the skin and will transmit continuous glucose values to an external unit or smartphone for over a full year, significantly improving the quality of life of diabetes patients. Founded in 2007, the company is part of the rainbow medical innovation house.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company based in Oldwick, New Jersey, dedicated to developing therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's pipeline includes several product candidates, such as PRV-031, a monoclonal antibody currently in Phase III trials for the interception of type 1 diabetes, and PRV-6527, an oral inhibitor in Phase IIa trials for Crohn’s disease. Other notable candidates include PRV-3279, which has completed Phase 1b trials for lupus, and PRV-101, a vaccine targeting coxsackie virus B infections. Additionally, PRV-015, an anti-IL-15 monoclonal antibody, is being developed for celiac disease and is currently in Phase IIb trials. Provention Bio's innovative approach emphasizes early intervention in disease progression, positioning the company as a potential leader in a new biopharmaceutical category focused on the prevention of chronic autoimmune and inflammatory conditions.